MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Net Debt 2011-2026 | SNOA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.29 M | -2.84 M | -3.4 M | -6.84 M | -2.67 M | -2.21 M | -3.36 M | -9.8 M | -17.3 M | -7.36 M | -6.05 M | -5.33 M | -5.96 M | -112 K | -1.83 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -112 K | -17.3 M | -5.36 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
178 M | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
285 M | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
94.8 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
338 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
317 M | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
-20.9 M | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
-521 K | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
-6.83 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-730 K | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-1.39 M | $ 2.07 | 0.98 % | $ 23.9 M | USA |